Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

BACKGROUND: Emerging SARS-CoV-2 variants and evidence of waning vaccine efficacy present substantial obstacles towards controlling the COVID-19 pandemic. Booster doses of SARS-CoV-2 vaccines might address these concerns by amplifying and broadening the immune responses seen with initial vaccination...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallory, Raburn M, Formica, Neil, Pfeiffer, Susan, Wilkinson, Bethanie, Marcheschi, Alex, Albert, Gary, McFall, Heather, Robinson, Michelle, Plested, Joyce S, Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Bin, Chau, Gordon, Robertson, Andreana, Maciejewski, Sonia, Hammond, Holly L, Baracco, Lauren, Logue, James, Frieman, Matthew B, Smith, Gale, Patel, Nita, Glenn, Gregory M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365313/
https://www.ncbi.nlm.nih.gov/pubmed/35963274
http://dx.doi.org/10.1016/S1473-3099(22)00420-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365313/
https://www.ncbi.nlm.nih.gov/pubmed/35963274
http://dx.doi.org/10.1016/S1473-3099(22)00420-0

Ejemplares similares